Larsen A, Petersson I, Svensson B
Department of Rheumatology, Västra sjukhuset, Västerås, Sweden.
Br J Rheumatol. 1989 Apr;28(2):124-7. doi: 10.1093/rheumatology/28.2.124.
The efficacy, tolerance, and safety of CPH 82 (semisynthetic lignan glycosides) (Conpharm AB) for patients with rheumatoid arthritis (RA) were assessed in a 12-week double-blind placebo-controlled study. Thirteen patients out of 15 in the CPH 82 group and 10 out of 15 in the placebo group completed the study. No improvement was seen in placebo treated patients. Patients treated with CPH 82 showed a statistically significant improvement in most clinical and immunological variables. Some patients treated with CPH 82 reported gastrointestinal discomfort (diarrhoea and abdominal pain).
在一项为期12周的双盲安慰剂对照研究中，评估了CPH 82（半合成木脂素糖苷）（康法姆制药公司）对类风湿性关节炎（RA）患者的疗效、耐受性和安全性。CPH 82组15名患者中有13名、安慰剂组15名患者中有10名完成了研究。接受安慰剂治疗的患者未见改善。接受CPH 82治疗的患者在大多数临床和免疫变量方面有统计学意义的改善。一些接受CPH 82治疗的患者报告有胃肠道不适（腹泻和腹痛）。
